---All---
  • ---All---
  • Accession
  • Catalog #

APG4C Antibody (N-term) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP1810a 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

APG4C Antibody (N-term) Blocking Peptide - Product info

Primary AccessionQ96DT6
Clone Names5011712
Calculated MW52497 Da

APG4C Antibody (N-term) Blocking Peptide - Additional info

Gene ID 84938
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1810a was selected from the N-term region of human Autophagy APG4C. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

APG4C Antibody (N-term) Blocking Peptide - Protein Information

Name ATG4C
Synonyms APG4C, AUTL1, AUTL3
Function
Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes
Cellular Location
Cytoplasm (Probable).
Tissue Location
Highly expressed in skeletal muscle, heart, liver and testis

APG4C Antibody (N-term) Blocking Peptide - Related products

AP1810a: ATG4C Antibody (N-term)

AP1810b: ATG4C Antibody (Center)

AP1810c: ATG4C Antibody (C-term)

AP1810d: ATG4C Antibody

AP1810e: ATG4C Antibody

AP1810f: ATG4C Antibody

AP3364a: Phospho-ATG4C-S451 Antibody

AP3392a: Phospho-ATG4C-S177 Antibody

AP3440a: Phospho-ATG4C-S398 Antibody

AP3456a: Phospho-ATG4C-S166 Antibody

RI10456: ATG4C predesign siRNA

LY10583a: ATG4C Over-expression Lysate

BP1810a: APG4C Antibody (N-term) Blocking Peptide

BP1810b: APG4C Antibody (Center) Blocking Peptide

BP1810c: APG4C Antibody (C-term) Blocking Peptide

BP1810d: APG4C Antibody (S398) Blocking Peptide

BP1810e: APG4C Antibody (S166) Blocking Peptide

BP3364a: Phospho-APG4C-S451 Antibody Blocking Peptide

BP3392a: Phospho-APG4C-S177 Antibody Blocking Peptide

BP3440a: Phospho-APG4C-S398 Antibody Blocking Peptide

BP3456a: Phospho-APG4C-S166 Antibody Blocking Peptide

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.

REFERENCES

Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)